Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 9/20 | 0.44 |
| ▸ | THRA | P10827 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6900551 | 0.84 | RAB9A (0.58) | ELANENPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL6900182 | 0.81 | RAB9A (0.42) | ELANENPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL15883997 | 0.81 | NPC1 (0.42) | ELANENPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL6900481 | 0.79 | MEN1 (0.42) | ELANETHRATHRBKMT2A | |
| SCHEMBL8130917 | 0.78 | RAB9A (0.56) | ELANENPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL8129293 | 0.78 | RAB9A (0.56) | ELANENPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL10494166 | 0.78 | RAB9A (0.56) | ELANENPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL8130837 | 0.78 | RAB9A (0.56) | ELANENPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL8130767 | 0.78 | RAB9A (0.56) | ELANENPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL12723378 | 0.78 | IDH1 (0.54) | NPC1CYP1A2CYP2C19RECQLRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302542-A1 | MONOBACTAMS | PFIZER INC | 2012-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302542-A1 | MONOBACTAMS | MGAM, MGAM2, BPGM | ELANE 250/4885THRA 2783/4885THRB 1915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.